Drug Profile
AZD 5099
Alternative Names: AZD5099Latest Information Update: 06 Aug 2012
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Antibacterials
- Mechanism of Action DNA gyrase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 30 Jun 2012 Discontinued - Phase-I for Bacterial infections in USA (IV)
- 30 Nov 2011 Suspended - Phase-I for Bacterial infections in USA (IV)
- 20 Jun 2011 Phase-I clinical trials in Bacterial infections (in volunteers) in USA (IV)